Keren Leshem CEO (Courtessy OCON)
OCON Therapeutics, a leading Israeli FemTech company recognized by the World Economic Forum, has secured $10 million in funding to advance its mission of transforming women’s healthcare, specifically with innovations in IUDs. This investment, led by RH Capital, fuels OCON’s development of groundbreaking drug delivery solutions for prevalent uterine conditions.
Contraception is central to women’s issues. The IUD (an intrauterine device) is a device implanted into the body and can be removed anytime. This gives women a higher level of freedom and control over their own bodies.
Led by CEO Keren Leshem, OCON leverages its patented 3D drug delivery system to create safer and more effective treatment options for common uterine pathologies. This funding empowers them to accelerate clinical programs, expand their product offerings, and ultimately bring their innovative solutions to women worldwide. Leshem spoke with Jewish Business News about the company.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“I feel privileged to be able to drive an innovative company that not only is led by women, but puts focus on the most prevalent diseases and conditions women face throughout their lives,” Keren Leshem, OCON’s CEO, told Jewish Business News “ I’m also so thankful to our investors and supporters. Bringing additional options for women that are safer and take into account their specific anatomy is what I and my team focus on everyday. These options are also for doctors and healthcare providers that are looking to bring innovation and treatments away from hospitals back into the community without the hassle of investing in equipment.”
“Having recruited our last patient in the IUB SEAD® RED® study we look forward to presenting the data that is currently looking very promising for heavy menstrual bleeding condition and related anemia and shame,” she added.
OCON stands out as a women-led company in the FemTech space, a field traditionally dominated by men. Leshem emphasizes OCON’s commitment to “focus on the most prevalent diseases and conditions women face throughout their lives.” Their goal is to provide “safer” and “more convenient” treatment options that cater to women’s specific needs.
OCON’s IUB SEAD® RED® study is nearing completion, with promising data for treating heavy menstrual bleeding, a condition impacting millions globally. This minimally invasive approach offers a potential solution for women experiencing anemia and related issues.
Building on the success of their IUB Ballerine®, used by over 150,000 women, OCON offers a range of solutions for abnormal uterine bleeding. Their IUB SEAD® platform provides a long-term hormonal approach, while IUB PRIMA® focuses on a non-hormonal option for shorter-term needs. This diversity empowers women to choose the treatment that best aligns with their individual health goals.
Their IUB SEAD® and IUB PRIMA® platforms offer personalized solutions for this common issue. IUB SEAD® provides a long-term hormonal approach with a single placement, potentially offering lasting relief. IUB PRIMA®, on the other hand, focuses on a convenient, non-hormonal treatment option for shorter-term needs. This diverse range empowers women to choose the treatment that best suits their individual health goals.
OCON Therapeutics remains at the forefront of women’s healthcare innovation. Their commitment to developing effective and personalized solutions for prevalent uterine conditions positions them as a leader in transforming women’s healthcare.
